# US 2013/0252979 A1 · Pharmaceutical compositions, dosage forms and new forms of the compound of mula (i), and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252979 A1
- Document ID: US20130252979A1
- Status: Published application
- Kind: A1
- Application number: 13/990,632
- Filed: 2011-12-05
- Published: 2013-09-26
- Earliest claimed: 2011-12-05
- Assignees: Portola Pharmaceuticals, Inc.
- Inventors: Ulrich Meier; Nicole Bieri; Dieter Becker; Julien Taillemite; Marie-Pierre Filliot; Tanja Meister
- Web page: https://patentgrep.com/patent/US20130252979A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral for mulation of this novel crystalline form, its preparation and use thereof.

## Claims

### Claim 1

The compound, [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, having the structural formula (I)
in a crystalline anhydrous form.

### Claim 2 (depends on 1)

The crystalline form of claim 1, characterized in that said form has at least one of the following characteristics:
(a) an X-ray powder diffraction pattern with peaks at 11.2, 15.8, and 26.4 degrees two theta (±0.2 degree) (CuKαλ=1.54059 Å), or an X-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1;
(b) a differential scanning calorimetry (DSC) melting followed by decomposition with an onset temperature of about 324° C. or a differential scanning calorimetry thermogram (DSC) substantially in accordance with that shown in FIG. 2;
(c) an FT-IR spectrum with the bands at 3427, 1716, 1637, 1514 and 1240 cm−1, or an FT-IR spectrum substantially in accordance with that shown in FIG. 3;
(d) an FT-Raman spectrum with the bands at 1216, 1176, 699, 343 and 133 cm−1, or a FT-Raman spectrum substantially in accordance with that shown in FIG. 4; and
(e) shifts at about 165.7, 152.3, 146.4, 141.2, 130.2, and 112.8 ppm (±0.2 ppm) when characterized by 13C solid state NMR.

### Claim 3 (depends on 1)

A crystalline form of claim 1, characterised by an X-ray powder diffraction pattern which
(i) has peaks at 11.2, 15.8, and 26.4 degrees two theta (±0.2 degree) (CuKαλ=1.54059 Å) or
(ii) has peaks at 11.2, 15.8, 17.2, 19.1, 24.8, 25.6, 26.4, 28.8, 29.4 and 32.0 two theta (±0.2 degree) (CuKαλ=1.54059 Å), or
(iii) is as essentially depicted in FIG. 1.

### Claim 4 (depends on 1)

A crystalline form of claim 1, characterised by an FT-Raman spectrum which
(a) has bands at 3427, 1716, 1637, 1514 and 1240 cm−1, or
(b) has bands at 1715, 1632, 1421, 1313, 1216, 1176, 919, 699, 343 and 133 cm−1; or
(c) is substantially in accordance with that shown in FIG. 4

### Claim 5 (depends on 1)

A crystalline form of claim 1, which shows shifts at
(a) 165.7, 152.3, 146.4, 141.2, 130.2, and 112.8 ppm (±0.2 ppm) when characterized by 13C solid state NMR; or
(b) about 165.7, 152.3, 146.4, 141.2, 130.2, 112.8, 101.0, 97.0, and 31.4 ppm (±0.2 ppm) when characterized by 13C solid state NMR.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A crystalline form of any one of claims 1-5 in 99, 95, 90, 85, 80, 75, 70, or 65% purity.

### Claim 7

A pharmaceutical composition comprising a crystalline form, according to any one of the preceding claims, and one or more pharmaceutically acceptable carrier or excipient.

### Claim 8 (depends on 7)

A composition according to claim 7 comprising an additional therapeutic agent.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A crystalline form according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 or 8, for use in treating or preventing a condition or disorder associated with platelet ADP receptor inhibition, in particular, P2Y12 inhibition.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The use of a crystalline form according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 or 8 for the manufacture of a medicament for treating or preventing a condition or disorder associated with platelet ADP receptor inhibition, in particular, P2Y12 inhibition.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method for treating or preventing a condition or disorder associated with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, which method comprises administering to a subject in need thereof a therapeutically effective amount of a crystalline form according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 or 8.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

A process for preparing a crystalline form according to any one of claims 1 to 6 comprising the steps of:
(a) adding, at a temperature between 20-30° C., an aqueous solution of a base, containing between 2.1 and 2.5 molar equivalents of a base, to a suspension of the acid of formula (II).
in water, wherein the suspension is initially at a temperature between 20-30° C.;
(b) heating the resulting solution to a temperature between 40-50° C.;
(c) filtering the resulting solution at a temperature between 40-50° C.;
(d) adding, at a temperature between 40-50° C., methanol or a 50-90% w/w methanol/water mixture, to form a supersaturated solution;
(e) adding, over a period of at least two hours, an aqueous acidic solution, containing 1 molar equivalent less than the amount of base used in step (a), to the supersaturated solution, wherein the acid has a pKa in the range of 3-6; wherein the temperature is kept at a temperature between 40-50° C.;
(f) cooling the resulting suspension from a temperature in the range of 40-50° C. to a temperature in the range of 20-30° C. over a period of at least 1.5 hours;
(g) separating and washing the crystals obtained at the end of step (f);
(h) and optionally drying the crystals.

### Claim 13

A solid pharmaceutical composition comprising: a) at least about 15% by weight the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier.

### Claim 14

A solid pharmaceutical composition comprising: a) about 15% to about 90% by weight the compound of formula (II), or a pharmaceutically acceptable salt thereof, relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier.

### Claim 15 (depends on 13, 14)

The solid pharmaceutical formulation of claim 13 or 14 wherein the carrier is selected from the group consisting of: an alkalizer, a disintegrant, a crystallization inhibitor, a solubilzer, a filler, a polymer, a glidant and a lubricant.

### Claim 16 (depends on 13, 14, 15)

The solid pharmaceutical formulation of any one of claims 13-15 wherein the alkalizer is selected from the group consisting of magnesium oxide, calcium carbonate, calcium phosphate and combinations thereof.

### Claim 17 (depends on 13, 14, 15, 16)

The solid pharmaceutical formulation of any one of claims 13-16 wherein the alkalizer is present in an amount of about 8% to about 90% by weight.

### Claim 18 (depends on 13, 14, 15, 16, 17)

The solid pharmaceutical formulation of any one of claims 13-17 wherein the alkalizer is present in an amount of about 11% by weight.

### Claim 19 (depends on 13, 14, 15, 16, 17, 18)

The solid pharmaceutical formulation of any one of claims 13-18 wherein the disintegrant is selected from the group consisting of a croscarmellose, sodium starch glycolate and crospovidone.

### Claim 20 (depends on 13, 14, 15, 16, 17, 18, 19)

The solid pharmaceutical formulation of any one of claims 13-19 wherein the disintegrant is crospovidone.

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The solid pharmaceutical formulation of any one of claims 13-20 wherein the disintegrant is present in an amount from at least about 2.5% by weight relative to the total weight of the overall pharmaceutical composition.

### Claim 22 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21)

The solid pharmaceutical formulation of any one of claims 13-21 wherein the disintegrant is present in an amount from at least about 2.5% to about 6% by weight relative to the total weight of the overall pharmaceutical composition.

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The solid pharmaceutical formulation of any one of claims 13-22 wherein the crystallization inhibitor is selected from the group consisting of a poly(vrnylpyrrolidone) and a hydroxypropylmethylcellulose.

### Claim 24 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The solid pharmaceutical formulation of any one of claims 13-23 wherein the hydroxypropylmethylcellulose has a viscosity of about 5 cP.

### Claim 25 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The solid pharmaceutical formulation of any one of claims 13-24 wherein the poly(vinylpyrrolidone) is PVP K30.

### Claim 26 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The solid pharmaceutical formulation of any one of claims 13-25 wherein the crystallization inhibitor is present in an amount of from at least about 3% by weight relative to the total weight of the overall pharmaceutical composition.

### Claim 27 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The solid pharmaceutical formulation of any one of claims 13-26 wherein the crystallization inhibitor is present in an amount from a at least 3% to about 11% by weight relative to the total weight of the overall pharmaceutical composition.

### Claim 28 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The solid pharmaceutical formulation of any one of claims 13-27 wherein the crystallization inhibitor is present in an amount from about 4.22% by weight.

### Claim 29 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The composition of any of one of claims 13-28 wherein the potassium salt of the compound of formula (II) is in form A, form B or form poly-D.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 29)

The composition of any of claim 29 wherein the form poly-D is the form according to any one of claims 1-6.

### Claim 31 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The composition according to any one of claims 13-30 which is in the form of a tablet or a capsule.

### Claim 32

A compressed solid oral dosage form comprising: a) solid pharmaceutical composition comprising: a) at least about 15% the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof by weight relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier.

### Claim 33 (depends on 32)

A compressed solid dosage form according to claim 32 wherein the active agent comprises the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof in a unit dosage of from between about 50 and 300 mg.

### Claim 34 (depends on 33)

A compressed solid dosage form according to claim 33 wherein the active agent comprises the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof in a unit dosage of from between about 75 and 100 mg.

### Claim 35 (depends on 33)

A compressed solid dosage form according to claim 33 wherein the active agent comprises the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof in a unit dosage of about 150 mg.

### Claim 36

A method of treating or preventing a thrombotic condition in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a solid pharmaceutical composition comprising: a) at least about 15% by weight the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier.

### Claim 37

A method to aid in dissolving the compound of formula (II), comprising the step of: providing the compound of formula (II) in a composition with an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide and calcium phosphate; a disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and crospovidone; and optionally a crystallization inhibitor selected from the group consisting of a poly(vinylpyrrolidone) and a hydroxypropylmethylcellulose in an amount of from at least about 3% by weight relative to the total weight of the overall pharmaceutical composition.

### Claim 38

A method of producing a solid pharmaceutical composition comprising the compound of formula (II); by contacting a) at least about 15% the compound of formula (II), or a pharmaceutically acceptable salt (for example the potassium salt), thereof by weight relative to the total weight of the overall pharmaceutical composition, with b) at least one pharmaceutically acceptable carrier.
